Literature DB >> 24033710

Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the ADAMTS13 gene.

Cecilie Utke Rank1, Johanna Kremer Hovinga, Magnus Mansouri Taleghani, Bernhard Lämmle, Jens Peter Gøtze, Ove Juul Nielsen.   

Abstract

Upshaw-Schulman syndrome (USS) is due to severe congenital deficiency of von Willebrand factor (VWF)-cleaving protease ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 domains, nr 13) activity resulting in the presence of unusually large forms of VWF in the circulation, causing intravascular platelet clumping and thrombotic microangiopathy. Our patient, a 26-year-old man, had attacks of thrombotic thrombocytopenic purpura (TTP) with thrombocytopenia and a urine dipstick positive for hemoglobin (4+), often as the only sign of hemolytic activity. He had ADAMTS13 activity of <1% of normal plasma without the presence of inhibitors of ADAMTS13. ADAMTS13 deficiency was caused by two new mutations of the ADAMTS13 gene: a deletion of a single nucleotide in exon17 (c. 2042 delA) leading to a frameshift (K681C fs X16), and a missense mutation in exon 25 (c.3368G>A) leading to p.R1123H. This case report confirms the importance of the analysis of the ADAMTS13 activity and its inhibitor in patients who have episodes of TTP, with a very low platelet count and sometimes without the classic biochemical signs of hemolysis.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  ADAMTS13; Upshaw-Schulman syndrome; genetic disorder; thrombotic thrombocytopenic purpura; von Willebrand factor

Mesh:

Substances:

Year:  2013        PMID: 24033710     DOI: 10.1111/ejh.12197

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  4 in total

1.  Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura.

Authors:  Marie Scully; Paul Knöbl; Karim Kentouche; Lawrence Rice; Jerzy Windyga; Reinhard Schneppenheim; Johanna A Kremer Hovinga; Michiko Kajiwara; Yoshihiro Fujimura; Caterina Maggiore; Jennifer Doralt; Christopher Hibbard; Leah Martell; Bruce Ewenstein
Journal:  Blood       Date:  2017-09-14       Impact factor: 22.113

2.  Adult-onset congenital thrombotic thrombocytopenic purpura caused by a novel compound heterozygous mutation of the ADAMTS13 gene.

Authors:  Johannes G Krabbe; Evelien W M Kemna; Annuska L M Strunk; Pieter A Jobse; P A Kramer; L D Dikkeschei; L P W J van den Heuvel; Rob Fijnheer; Leo F Verdonck
Journal:  Int J Hematol       Date:  2015-08-13       Impact factor: 2.490

3.  Effect of Acute Myocardial Infarction on a Disintegrin and Metalloprotease with Thrombospondin Motif 13 and Von Willebrand Factor and Their Relationship with Markers of Inflammation.

Authors:  Abeer A Al-Masri; Syed Shahid Habib; Ahmad Hersi; Hana Al Zamil
Journal:  Int J Vasc Med       Date:  2020-02-11

4.  Combined study of ADAMTS13 and complement genes in the diagnosis of thrombotic microangiopathies using next-generation sequencing.

Authors:  Teresa Fidalgo; Patrícia Martinho; Catarina S Pinto; Ana C Oliveira; Ramon Salvado; Nina Borràs; Margarida Coucelo; Licínio Manco; Tabita Maia; M João Mendes; Rafael Del Orbe Barreto; Irene Corrales; Francisco Vidal; M Letícia Ribeiro
Journal:  Res Pract Thromb Haemost       Date:  2017-06-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.